Results 101 to 110 of about 21,275,692 (207)

Gut microbiota alterations in patients with non-small-cell lung cancer undergoing chemoradiotherapy. [PDF]

Mol Oncol
Nymoen HM, Zhao Z, Horndalsveen H, Bjaanæs MM, Grønberg BH, Halvorsen T, Madebo T, Aanerud M, Koivunen J, Oselin K, Cicenas S, Helbekkmo N, Ahvonen J, Silvoniemi M, Alver TN, Dalen T, Öjlert ÅK, Farooqi SJ, Helland Å, Haakensen VD.   +19 more
europepmc   +1 more source

Molecular Residual Disease in Non-Small Cell Lung Cancer: Technology or Patient Outcomes? [PDF]

J Pers Med
Walker PR.
europepmc   +1 more source

Current status and future of immunotherapy in non-small cell lung cancer

Around 85% of lung cancer cases are non-small cell lung cancer (NSCLC). Recent treatment used for NSCLC has been changed to immunotherapy, especially immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 and CTLA-4 inhibitors. These treatments increase
Tsai, Ping Lien
core  

HSP90 as a novel molecular target in non-small-cell lung cancer

, 2016
Khashayar Esfahani, Victor Cohen Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada Abstract: Lung cancer remains the most lethal cancer, with over 160,000 annual deaths in the USA alone.
Esfahani K, Cohen V
core  

Angiogenesis and Non Small Cell Lung Cancer

Balkan Journal of Medical Genetics, 2008
Metodieva S
doaj   +1 more source

Management of brain metastases in older adults with non-small cell lung cancer. [PDF]

Front Oncol
Belone Lopes J, Schep D, Sahgal A, Rodrigues RF, Menjak IB.   +4 more
europepmc   +1 more source

N1‐methylpseudouridine modification level correlates with protein expression, immunogenicity, and stability of mRNA

MedComm
Shaoyi Chen, Zheng Liu, Jingsheng Cai, Haoran Li, Mantang Qiu   +4 more
doaj   +1 more source

Antibody-Drug Conjugates in Non-small Cell Lung Cancer. [PDF]

Drugs
Zullo L, Bortolot M, Ogliari FR, Saw SPL, van Geel R, Ter Heine R, Sadowska A, Remon J, Hendriks L.   +8 more
europepmc   +1 more source

Patients? perceptions of the value of PET in diagnosis and management of non-small call lung cancer, CHERE Working Paper 2007/5 [PDF]

A randomized controlled trial comparing the use of PET versus no PET provided the opportunity to investigate the value patients placed on any additional information provided by the PET scan.
Marion Haas, Siggi Zapart, Rosalie Viney
core  

Erratum: AGTR1 signaling contributes to tumor immunity and therapy response in non-small cell lung cancer. [PDF]

Mol Ther Oncol
Ikoma T, Araki K, Kitagawa M, Makihara N, Nagata Y, Fujii K, Okuno Y, Yuta Okazaki KK, Nakanishi K, Sanada Y, Yoshida K, Nakahama K, Takeyasu Y, Katsushima U, Yamanaka Y, Ikeda S, Yoshioka H, Shimizu T, Kurata T.   +18 more
europepmc   +1 more source